Akebia Therapeutics, Inc. (AKBA) Dividend History

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. The company's lead product, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor intended to treat anemia associated with chronic kidney disease. Akebia aims to address unmet medical needs in renal conditions through innovative treatments.

245 First Street, Cambridge, MA, 02142
Phone: 617-871-2098
Website: https://www.akebia.com

Dividend History

Akebia Therapeutics, Inc. currently does not pay dividends

Company News

  • Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

    Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.

    GlobeNewswire Inc.
  • Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

    Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
  • Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

    Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from Benzinga Pro. RH shares jumped 9.4% to $324.99 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. Binah Capital Group, Inc. (NASDAQ: BCG) gained 149% to $23.65 in pre-market trading after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 49.5% to $4.89 in pre-market trading. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares rose 36.3% to $0.1220 in pre-market ...

    Benzinga
    Featured Companies: ABTS AVTX BCG CC GCT GCTS HKIT LGVN MLKN RH SOBR UGRO XXII
  • 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%

    Analysts say these are penny stocks to buy but are they worth the risk? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: ESPR XERS
  • Wall Street Breakfast: The Week Ahead

    Investors head into next week with the debt ceiling crisis resolved for the near term.

    Seeking Alpha
    Featured Companies: BF.A BMY BOX CASY CAT CCI CPB CSCO DLO DOCU FERG GILD GME GTLB IEP LLY MRK MTN NSA PINE PSTL REGN RL RYN SAIC SFIX SIG SJM STEP STKL TD UNH
Page data last updated 07/23/2025 08:07:02 UTC